Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (1944)	3/26/2002 4:41:05 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 10345

off of CreditWatch...... Tuesday March 26, 4:28 pm Eastern Time TEXT-S&P cuts Elan Corp Plc corporate credit rating (UPDATE: Press release provided by Standard & Poor's) NEW YORK, March 26 - Standard & Poor's said today that it lowered its corporate credit rating on specialty pharmaceutical company, Elan Corp. PLC (NYSE:ELN - news), to triple-'B'-minus from triple-'B', based on Elan's reduced earnings and cash flow expectations and expected, significant debt-financed product acquisitions over the next two years. Also, the senior unsecured debt ratings on Dublin, Ireland-based Elan were lowered to triple-'B'-minus from triple-'B'. All ratings were removed from CreditWatch, where they were placed on Feb. 6, 2002. Total rated debt is $2.7 billion. The outlook is stable. ``The outlook assumes that Elan will maintain a high level of financial flexibility, as it funds its planned future product acquisitions, as well as successfully restores the company to higher earnings growth,'' said Standard & Poor's credit analyst Arthur Wong. The low investment-grade ratings on Elan reflect the company's still solid core pharmaceutical business and significant financial flexibility, offset by its near-term challenges in expanding its product sales and the increased likelihood of major debt-financed product acquisitions. Elan continues to focus on expanding its self-marketed drug portfolio that accounts for nearly 65% of the revenue base (excluding one-time product divestitures in 2001), with the rest produced from contract revenues. The company's drug portfolio is diverse, led by muscle spasticity treatment, Zanaflex; the pain medication, Skelaxin; and the invasive fungal treatment, Abelcet. Each of these products generates over $100 million in annual sales. In 2001, Elan divested a number of its smaller, slower selling products in order to increase its focus on its larger products. A complete list of ratings is available to RatingsDirect subscribers at www.ratingsdirect.com, as well as on Standard & Poor's public web site at www.standardandpoors.com under Ratings Actions/Newly Released Ratings.